The survey was completed between October 9 and October 21, 2008. Ophthalmologists across the nation were invited via e-mail to enter the online survey, and those who treated 4 or more moderate to severe dry eye patients per month were asked to complete the survey. A total of 245 completed the survey, including 51 corneal specialists, 153 comprehensive/general ophthalmologists and 41 from other ophthalmology specialty categories. A survey sample of this size has a 95% confidence interval of + 6%.
About Dry Eye
Dry eye can result from a wide range of conditions, including aging; hormonal changes; environmental conditions such as cigarette smoke, dust, air conditioning or sun exposure; cold or allergy medications; as a side effect of vision correction surgery or cosmetic eyelid surgery; contact lens use; and Sjogren's syndrome. Despite decades of research and advances in treatment, dry eye syndrome remains one of the most common and challenging issues clinicians deal with in practice. Because it is not a condition identified by a specific pathological mechanism, no single therapeutic solution works for all patients.
Lacrisert has been FDA-approved for use in patients with moderate to
severe dry eye and available by prescription for more than two decades.
Unlike artificial tear substitutes that have a residence time measured in
minutes, Lacrisert provides continual lubrication and protection to the
surface of the eye for all-day relief. Lacrisert acts to stabilize and
thicken the pre-corneal tear film and prolong the tear film breakup time,
which is usually accelerated in patients with dry eye states. Inform
|SOURCE Aton Pharma, Inc.|
Copyright©2008 PR Newswire.
All rights reserved